Platinum-based chemotherapy in lung cancer affects the expression of certain biomarkers including ERCC1

Pathology and Oncology Research

Volumn 15, Issue 3, 2009, Pages 445-450

  Pápay, Judit ^a   Sápi, Zoltán ^a   Egri, Gábor ^b   Gyulai, Márton ^c   Szende, Béla ^a   Losonczy, György ^a   Tímár, József ^a   Moldvay, Judit ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Bajcsy Hospital   (Hungary)

^c Pest County Institute of Pulmonology   (Hungary)

Author keywords

Chemotherapy; Immunohistochemistry; Lung cancer; Molecular biology; Neoadjuvant treatment

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FAS LIGAND; GEMCITABINE; INHIBITOR OF APOPTOSIS PROTEIN; KI 67 ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; BRONCHOSCOPY; BRONCHUS BIOPSY; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; LUNG CANCER; MALE; PHENOTYPE; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PLATINUM COMPOUNDS; TUMOR MARKERS, BIOLOGICAL;

EID: 73449084433     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12253-009-9155-z     Document Type: Article

References (16)

1. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 2002-2004 Incidence and Mortality Web-based Report Version. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2007
2. J Noble PM Ellis JA Mackay, et al. 2006 Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline J Thorac Oncol 9 1042 58 10.1097/01243894-200611000-00021
3. K Junker K Langner F Klinke, et al. 2001 Grading of tumor regression in non-small cell lung cancer: morphology and prognosis Chest. 120 5 1584 91 10.1378/chest.120.5.1584 1:STN:280:DC%2BD3MnmslCjtA%3D%3D 11713138 (Pubitemid 33078476)
4. JL Morero C Poleri C Martin, et al. 2007 Influence of apoptosis and cell cycle regulator proteins on chemotherapy response and survival in stage IIIA/IIIB NSCLC patients J Thorac Oncol. 4 293 8
5. K Ikuta K Takemura M Kihara, et al. 2005 Defects in apoptotic signal transduction in cisplatin-resistant non-small cell lung cancer cells Oncol Rep. 13 6 1229 34 1:CAS:528:DC%2BD2MXltV2ksLc%3D 15870947
6. M Filipits R Pirker A Dunant, et al. 2007 Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program J Clin Oncol. 25 19 2735 40 10.1200/JCO.2006.08.2867 1:CAS:528:DC%2BD2sXosValtLs%3D 17602078 (Pubitemid 47123181)
7. KA Olaussen A Dunant P Fouret, et al. 2006 DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 983 91 10.1056/NEJMoa060570 1:CAS:528:DC%2BD28XpsFKmtLw%3D 16957145 (Pubitemid 44343542)
8. JR Rigas K Kelly 2007 Current treatment paradigms for locally advanced non-small cell lung cancer J Thorac Oncol. 2 Suppl 2 S77 85 10.1097/01.JTO. 0000269735.21209.bc 17589303
9. D Gilligan M Nicolson I Smith, et al. 2007 Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review Lancet. 369 9577 1929 37 10.1016/S0140-6736(07)60714-4 1:CAS:528:DC%2BD2sXmt1yitLg%3D 17544497 (Pubitemid 46874559)
10. F de Marinis B Tedesco S Treggiari, et al. 2007 Role of induction chemotherapy in resectable N2 non-small cell lung cancer J Thorac Oncol. 5 Suppl 5 S31 4 10.1097/01.JTO.0000268639.48450.a4 (Pubitemid 47181737)
11. RP Abratt JS Lee JY Han, et al. 2006 Phase II trial of gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable non-small cell lung cancer J Thorac Oncol. 2 135 40 10.1097/01243894-200602000- 00006
12. TE Stinchcombe MA Socinski 2007 The role of induction therapy for resectable non-small cell lung cancer Drugs. 67 3 321 32 10.2165/00003495- 200767030-00001 1:CAS:528:DC%2BD2sXkvFehsLk%3D 17335293 (Pubitemid 46425548)
13. R De Pauw JP van Meerbeeck 2007 Neoadjuvant chemotherapy in the treatment of nonsmall-cell lung cancer Curr Opin Oncol. 19 2 92 7 10.1097/CCO. 0b013e328011bed9 17272979 (Pubitemid 46204346)
14. AP Meert B Martin JM Verdebout, et al. 2004 Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer Lung Cancer. 44 3 295 301 10.1016/j.lungcan.2003.12.009 15140542 (Pubitemid 38609437)
15. Lang DS, Droemann D, Schultz H et al (2007) A novel human ex vivo model for the analysis of molecular events during lung cancer chemotherapy. Respir Res. 14;8:43
16. T Fujii S Toyooka K Ichimura, et al. 2008 ERCC1 protein expression predicts the response of cisplatin-based neoadjuvant chemotherapy in non-small-cell lung cancer Lung Cancer 59 3 377 84 10.1016/j.lungcan.2007.08.025 17905465 (Pubitemid 351335101)